A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol.
OBJECTIVE
There are no reports examining the safety of taking both topiramate and aripiprazole together with alcohol. The ultimate aim for this research is to determine whether this combination is safe and is superior to either drug taken alone in reducing alcohol use in alcohol dependent patients.


METHODS
This was an open-label trial. Thirteen heavy drinking participants not seeking treatment for alcoholism were randomized. Participants were titrated up to 300 mg of topiramate and 30 mg of aripiprazole a day over 35 days. Participants reported adverse events (AEs) daily alcohol use and participated in an alcohol challenge session (ACS).


RESULTS
The eight participants who completed the study achieved the maximum doses of drugs. The AEs of the drugs would suggest that the AEs profile is broader but not additive. Alcohol use from the 28 days before screening to the seven days before the ACS was reduced (p = 0.08).


CONCLUSIONS
There was no evidence that AEs of aripiprazole and topiramate are additive and can, therefore, be administered safely together with a modest amount of alcohol. There was also a trend for a reduction of alcohol use by participants. This finding has implications for further investigation of this combination of drugs for alcohol dependence.
Kenna
George A
GA
Department of Psychiatry and the Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island, USA. George_Kenna@Brown.edu
Leggio
Lorenzo
L
Swift
Robert M
RM
D000328:Adult; D000428:Alcohol Drinking / Q000009:adverse effects*; D000437:Alcoholism / Q000534:rehabilitation; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068180:Aripiprazole; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects*; D000077236:Topiramate; D055815:Young Adult
D014150:Antipsychotic Agents; D018696:Neuroprotective Agents; D010879:Piperazines; D015363:Quinolones; D000077236:Topiramate; D005632:Fructose; D000068180:Aripiprazole